In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cost, Risk and Scientific Conservatism Dramatically Limit the Dealmaking for Heart Medicines.

Executive Summary

Although cardiovascular drugs represent the biggest category in pharmaceutical sales, dealmaking has been surprisingly slight compared to other therapeutic areas. The low activity level reflects minimal progress in creating novel medicines and the clinical risk and cost innovators face.
Advertisement

Related Content

Clinical Update (02/2007)
AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness
Reformulation has Ruled in Neurology Dealmaking--Until Now
FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque
FoxHollow and Merck Expand Alliance, Aim at Vulnerable Plaque
Anatomy of a Deal: Inside the AstraZeneca/ AtheroGenics Agreement
FoxHollow/Merck R&D Deal: The Value of Plaque
Reconfiguring DTC with Patient Behavior in Mind

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel